Datasets
Therapeutic Areas
All
Metabolic
Neurology
Immunology
Ophthalmology
Renal
Respiratory
Respiratory
Key Variables
Structured:
Smoking status
Allergy test results
Oral corticosteroid bursts
ED visits & hospitalisations
Biologic agent & start date
ICS/LABA & LAMA regimen
Comorbidities
Abstracted with AI:
FEV1, FEV1/FVC ratio
Eosinophil count & percentage
FeNO
Insights
T2 vs. non-T2 biologic response
Biologic switching patterns & drivers
Early biologic impact on OCS dependence
Exacerbation risk by phenotype
Respiratory
Key Variables
Structured:
Smoking status
Oral corticosteroid bursts
Inhaled therapy regimen
ED visits & hospitalizations
Biologic agent & start date
Comorbidities
Abstracted with AI:
FEV1, FEV1/FVC ratio
Eosinophil count & percentage
Insights
Exacerbation risk by GOLD stage & phenotype
Eosinophil-guided biologic response
Triple therapy adoption & outcomes
OCS dependence & cumulative burden
Renal
Key Variables
Structured:
CKD stage (1–5 / ESKD)
eGFR & eGFR slope
UACR & UPCR
SGLT2 inhibitor use
RAAS agent use
MRA use
Immunosuppressive therapy
Comorbidities
Abstracted with AI:
Glomerular disease subtype
Biopsy findings (chronicity, % crescents)
Insights
SGLT2 & finerenone real-world eGFR outcomes
GN subtype progression & treatment response
Pathways to dialysis & transplant
Proteinuria reduction by therapy class
Ophthalmology
Key Variables
Structured:
AMD subtype
Visual acuity
Anti-VEGF agent & injection date
Comorbidities
Abstracted with AI:
Central Subfield Thickness (CST)
Macular Cube Volume
Cube Average Thickness
Cystoid Macular Edema
Intraretinal and Subretinal Fluid
Insights
Predictors of dry-to-wet conversion
Anti-VEGF treatment intervals & switching
GA progression by subtype & location
Fibrosis & vision loss trajectories
Ophthalmology
Key Variables
Structured:
DR severity stage
DME status
Visual acuity
CST & macular volume
Anti-VEGF agent & injection date
Systemic diabetes medications
Comorbidities
Abstracted by AI:
Central Subfield Thickness (CST)
Macular Cube Volume
Cube Average Thickness
Cystoid Macular Edema
Intraretinal and Subretinal Fluid
Insights
NPDR-to-PDR progression predictors
Anti-VEGF response & treatment intervals
Systemic disease control & visual outcomes
DME development & resolution patterns
Neurology
Key Variables
Structured:
JCV antibody results
Infection events
Lymphocyte counts & safety labs
Encounter frequency & visit cadence
Comorbidities
Abstracted with AI:
Estimated EDSS
Relapse events
MRI results & progression
DMT agent, initiation & discontinuation reason
DMT prescription date
Infusion reactions
Concomitant medications
Patient-reported symptoms
Insights
DMT switching patterns & outcomes
High- vs. moderate-efficacy therapy sequences
Relapse frequency & disability progression
Real-world DMT discontinuation & persistence
Neurology
Key Variables
Structured:
CSF & blood biomarkers (Aβ42, tau, p-tau, NfL)
APOE genotype
Anti-amyloid therapy & start date
Cholinesterase inhibitors & memantine
Comorbidities
Abstracted with AI:
MMSE, MoCA, ADAS-Cog
CDR & FAST staging
Neuropsychiatric symptom scores
Disease subtype & severity
ARIA incidence
Amyloid & tau PET findings
Insights
Cognitive trajectories by biomarker profile
Real-world ARIA rates & management
Anti-amyloid therapy persistence & discontinuation
Early vs. late treatment initiation outcomes
Neurology
Key Variables
FcRn & complement inhibitor prescriptions & start date
Corticosteroid & immunosuppressant prescriptions
Encounter frequency & visit cadence
Comorbidities
AChR & MuSK antibody status
MG-ADL scores
MGFA clinical classification
Ocular vs. generalized disease
Therapy discontinuation reason
Insights
FcRn vs. complement inhibitor sequencing & outcomes
Steroid burden & steroid-sparing response
Exacerbation & crisis rates by treatment
Real-world biologic persistence & switching
Metabolic
Key Variables
Structured:
ALT, AST, GGT, bilirubin
FIB-4, APRI
HbA1c, fasting glucose
Lipid panel
BMI & weight
GLP-1 agonist use
SGLT2 inhibitor use
Comorbidities
Abstracted with AI:
Fibrosis stage
Steatosis severity
NAS score
FibroScan (kPa, CAP score)
MRI-PDFF
Ascites & signs of cirrhosis
Insights
Fibrosis progression predictors
GLP-1 & SGLT2 real-world response
Metabolic comorbidity burden & outcomes
Treatment initiation timing & patterns
Immunology
Key Variables
Structured:
Subtype
Disease behavior
Biologic use & start date
JAK inhibitor use
Immunomodulator use
Corticosteroid use
CRP, ESR, fecal calprotectin
Surgical procedure type & date
Comorbidities
Abstracted with AI:
Mayo Endoscopic Score
SES-CD score
Harvey-Bradshaw Index / CDAI
Disease location & extent
Stricture, fistula & abscess presence
Insights
Biologic & JAK inhibitor sequencing patterns
Drug monitoring & dose optimization
Disease behavior progression & surgery risk
Endoscopic vs. clinical remission rates